Unlike traditional drug development, cell therapy logistics require extremely close, integrated relationships with contract research (CRO) and manufacturing (CDMO) organizations. Due to the direct line from patient to manufacturing and back, these partners function as critical extensions of the core team to ensure timeliness and safety.

Manufacturing induced pluripotent stem cells (iPSCs) is a highly manual, 'artisanal process' dependent on the subjective skill of individual scientists. This 'magic hands' bottleneck is a major barrier to scaling personalized therapies. Cellino's strategy is to automate these steps with AI and lasers to solve this core challenge.

The focus in advanced therapies has shifted dramatically. While earlier years were about proving clinical and technological efficacy, the current risk-averse funding climate has forced the sector to prioritize commercial viability, scalability, and the industrialization of manufacturing processes to ensure long-term sustainability.

The CTMC model, by being physically and collaboratively embedded within MD Anderson Cancer Center, creates a tight feedback loop. This "patient-adjacent" approach accelerates IND filings, regulatory interactions, and clinical study activation by streamlining logistics, communication, and regulatory processes.

To expand cell therapy globally, building facilities is insufficient. The key is forming alliances that transfer manufacturing processes, analytics knowledge, and provide local regulatory support to enable regions like Brazil to adopt these complex treatments and build self-sufficient ecosystems.

Unlike traditional pharmaceuticals, cell therapies are patient-specific (one batch, one patient). This makes the centralized global manufacturing model inefficient. A decentralized, local production network is essential for global accessibility and scalability, fundamentally changing the supply chain strategy.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

The use of low-cost, scalable plastic tank bioreactors eliminates the need for traditional, expensive GMP facilities. This allows companies to convert cheap, underutilized office space into production labs, enabling a novel business model of decentralized, onshore manufacturing that dramatically lowers real estate and operational costs.

Contrary to the belief that CAR-T therapies require inpatient hospitalization, about 50% of Carvykti infusions occur in an outpatient setting. This flexibility allows more hospitals to offer the treatment and makes it more accessible for patients, revolutionizing the delivery model for complex cell therapies.